GSK plc
Search results
AstraZeneca is a global, science-led biopharmaceutical business and our innovative medicines are used by millions of patients worldwide.
AstraZeneca's primary listing is on the London Stock Exchange and is a constituent of the FTSE 100 Index; it also has a secondary listing on the Nasdaq Stockholm. AstraZeneca has one of the highest market capitalisations of pharmaceutical companies worldwide.
Our company. We are a global, science-led, patient-focused pharmaceutical company. We are dedicated to transforming the future of healthcare by unlocking the power of what science can do for people, society and the planet.
To tackle some of the world’s greatest healthcare challenges, we’ve created an inspiring working environment with world-class talent and opportunities. In India, we merge our brightest minds and cutting-edge resources to make a real difference to lives the world over. Search jobs.
At AstraZeneca we’re united by our desire to push the boundaries of science to deliver life-changing medicines. We know it’s how we will continue to transform the lives of millions of patients around the world while delivering value to our employees, our communities, and the environment.
Jun 13, 2022 · The AstraZeneca vaccine has an efficacy of 72% against symptomatic SARS-CoV-2 infection, as shown by the primary analysis of data irrespective of interdose interval from trial participants who received 2 standard doses with an interval varying from about 4 to 12 weeks.
Mar 22, 2021 · Results from the long-awaited US trial of the Oxford-AstraZeneca Covid vaccine are out and confirm that the shot is both safe and highly effective. More than 32,000 volunteers took part, mostly...
Jul 1, 2024 · AstraZeneca’s Imfinzi (durvalumab) and Lynparza (olaparib) have been recommended for approval in the European Union (EU) as treatment for certain patients with primary advanced or recurrent endometrial cancer. Imfinzi plus chemotherapy as 1st-line treatment followed by Lynparza and Imfinzi has been recommended for patients with mismatch repair proficient (pMMR) disease.
Apr 6, 2022 · AstraZeneca’s Global Technology Centre in India increases its focus on driving innovation – repositioning itself as a Global Innovation and Technology Centre. PUBLISHED 6 April 2022. Chennai, April 6, 2022: AstraZeneca India Private Limited (AZIPL), the Global Capability Centre (GCC) of AstraZeneca announced today that they have ...
Mar 25, 2021 · AstraZeneca has updated the efficacy result of its coronavirus vaccine trial in the US, after health officials insisted they wanted to include the latest information.
